Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis.
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
18 Feb 2022
18 Feb 2022
Historique:
pubmed:
16
9
2021
medline:
22
2
2022
entrez:
15
9
2021
Statut:
ppublish
Résumé
Limited data are available regarding clinical outcomes of valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) following the United States Food and Drug Administration approval of ViV TAVI in 2015. The aim of this study was to evaluate in-hospital, 30-day, and 6-month outcomes of ViV TAVI versus repeat surgical aortic valve replacement (SAVR) in patients with a failed aortic bioprosthetic valve. This retrospective cohort study identified patients who underwent ViV TAVI or repeat SAVR utilising the Nationwide Readmission Database from 2016 to 2018. Primary outcomes were all-cause readmission (at 30 days and 6 months) and in-hospital death. Secondary outcomes were in-hospital stroke, pacemaker implantation, 30-day/6-month major adverse cardiac events (MACE), and mortality during readmission. Propensity score-matching (inverse probability of treatment weighting) analyses were implemented. Out of 6,769 procedures performed, 3,724 (55%) patients underwent ViV TAVI, and 3,045 (45%) underwent repeat SAVR. ViV TAVI was associated with lower in-hospital all-cause mortality (odds ratio [OR] 0.42, 95% confidence interval [CI]: 0.20-0.90, p=0.026) and a higher rate of 30-day (hazard ratio [HR] 1.46, 95% CI: 1.13-1.90, p=0.004) and 6-month all-cause readmission (HR 1.54, 95% CI: 1.14-2.10, p=0.006) compared with repeat SAVR. All secondary outcomes were comparable between the two groups. ViV TAVI was associated with lower in-hospital mortality but higher 30-day and 6-month all-cause readmission. However, there was no difference in risk of in-hospital stroke, post-procedure pacemaker implantation, MACE, and mortality during 30-day and 6-month readmission compared with repeat SAVR, suggesting that ViV TAVI can be performed safely in carefully selected patients.
Sections du résumé
BACKGROUND
BACKGROUND
Limited data are available regarding clinical outcomes of valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) following the United States Food and Drug Administration approval of ViV TAVI in 2015.
AIMS
OBJECTIVE
The aim of this study was to evaluate in-hospital, 30-day, and 6-month outcomes of ViV TAVI versus repeat surgical aortic valve replacement (SAVR) in patients with a failed aortic bioprosthetic valve.
METHODS
METHODS
This retrospective cohort study identified patients who underwent ViV TAVI or repeat SAVR utilising the Nationwide Readmission Database from 2016 to 2018. Primary outcomes were all-cause readmission (at 30 days and 6 months) and in-hospital death. Secondary outcomes were in-hospital stroke, pacemaker implantation, 30-day/6-month major adverse cardiac events (MACE), and mortality during readmission. Propensity score-matching (inverse probability of treatment weighting) analyses were implemented.
RESULTS
RESULTS
Out of 6,769 procedures performed, 3,724 (55%) patients underwent ViV TAVI, and 3,045 (45%) underwent repeat SAVR. ViV TAVI was associated with lower in-hospital all-cause mortality (odds ratio [OR] 0.42, 95% confidence interval [CI]: 0.20-0.90, p=0.026) and a higher rate of 30-day (hazard ratio [HR] 1.46, 95% CI: 1.13-1.90, p=0.004) and 6-month all-cause readmission (HR 1.54, 95% CI: 1.14-2.10, p=0.006) compared with repeat SAVR. All secondary outcomes were comparable between the two groups.
CONCLUSIONS
CONCLUSIONS
ViV TAVI was associated with lower in-hospital mortality but higher 30-day and 6-month all-cause readmission. However, there was no difference in risk of in-hospital stroke, post-procedure pacemaker implantation, MACE, and mortality during 30-day and 6-month readmission compared with repeat SAVR, suggesting that ViV TAVI can be performed safely in carefully selected patients.
Identifiants
pubmed: 34521614
pii: EIJ-D-21-00472
doi: 10.4244/EIJ-D-21-00472
pmc: PMC9724873
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227-1237Commentaires et corrections
Type : CommentIn
Références
JACC Cardiovasc Interv. 2021 Jan 25;14(2):211-220
pubmed: 33478639
J Am Coll Cardiol. 2020 Aug 4;76(5):489-499
pubmed: 32731926
Methodist Debakey Cardiovasc J. 2017 Jul-Sep;13(3):132-141
pubmed: 29743998
J Geriatr Cardiol. 2018 Feb;15(2):123-130
pubmed: 29662505
JAMA. 2014 Jul;312(2):162-70
pubmed: 25005653
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
JAMA Cardiol. 2019 Jan 1;4(1):71-80
pubmed: 30516815
J Am Coll Cardiol. 2017 May 9;69(18):2253-2262
pubmed: 28473128
Heart. 2017 Nov;103(21):1696-1703
pubmed: 28432156
Health Serv Res. 2014 Feb;49(1):284-303
pubmed: 23855598
Heart Lung. 2020 Mar - Apr;49(2):186-192
pubmed: 31690493
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
JACC Cardiovasc Interv. 2020 Mar 23;13(6):765-774
pubmed: 31954671
JACC Cardiovasc Interv. 2019 Sep 23;12(18):1811-1822
pubmed: 31537280
J Am Coll Cardiol. 2010 Jun 1;55(22):2413-26
pubmed: 20510209
JACC Cardiovasc Interv. 2015 Nov;8(13):1748-57
pubmed: 26476610
Indian Heart J. 2019 Jul - Aug;71(4):291-296
pubmed: 31779855
BMJ Open. 2021 Mar 17;11(3):e044010
pubmed: 33737435
Circulation. 2021 Feb 2;143(5):e35-e71
pubmed: 33332149
Eur Heart J. 2020 Aug 1;41(29):2747-2755
pubmed: 32445575
Am J Cardiol. 2018 Jan 1;121(1):73-77
pubmed: 29103601
N Engl J Med. 2017 Nov 9;377(19):1847-1857
pubmed: 29117490
J Am Heart Assoc. 2020 Oct 20;9(19):e018506
pubmed: 32954917
Ann Thorac Surg. 2015 Oct;100(4):1298-304; discussion 1304
pubmed: 26209480
Sci Rep. 2020 Sep 23;10(1):15568
pubmed: 32968104
Am J Cardiol. 2020 May 1;125(9):1378-1384
pubmed: 32139158
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732